History of LAM
Download Key Milestones (pdf)
Download Progress In LAM (pdf)
Key Milestones
1918 - First case of LAM in a tuberous sclerosis (TSC) patient
1937 - First description of LAM in a patient without tuberous sclerosis
1993 - Discovery of tuberous sclerosis 2 (TSC2) gene
1995 - The LAM Foundation is founded by Sue Byrnes, whose daughter Andrea Byrnes was diagnosed with LAM.
Sue successfully lobbied Congress to convince the National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), to develop a LAM patient registry, including a tissue bank. The patient registry has helped physicians and scientists become more knowledgeable about LAM and stimulated valuable scientific research.
1996 - First LAM Foundation research grant funded
1997 - Discovery of tuberous sclerosis 1 (TSC1) gene
NHLBI LAM patient registry established
LAM Foundation holds first annual International LAM Research Conference (LAMposium)
1998 - Investigators identify evidence of TSC gene involvement in LAM
LAM Foundation funds first scientific publication
1999 - Discovery that TSC2 gene controls cell size in fruit fly eyes
2000 - LAM Foundation Scientists discover that LAM is caused by TSC gene mutation
2001 - TSC proteins linked to regulation of cell-signaling pathway (Akt), important for cell growth
2002 - Metastatic mechanism for LAM discovered (Akt signaling) and sirolimus is found to shrink kidney tumors in TSC mice by blocking Akt signaling
2003 - Cincinnati-based angiomyolipoma sirolimus trial begins
2004 - First $1 million fundraising year
2005 - Multicenter International LAM Efficacy of Sirolimus (MILES) Trial developed
The LAM Foundation celebrates 10 years of providing support and leading research effortsto find a cure for LAM
2006 - Multicenter International LAM Efficacy of Sirolimus (MILES) Trial begins enrolling patients in a study of sirolimus as a potential treatment for LAM
2007 - Inaugural Meeting of the Worldwide LAM Patient Coalition (WLPC)


